| 1 | The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes. (Rojas M, Heuer LS, Zhang W, Chen YG, Ridgway WM) Front Immunol 2022;13:918837 1 Citation |
| 1 | Congenic mapping identifies a novel Idd9 subregion regulating type 1 diabetes in NOD mice. (Lin B, Ciecko AE, MacKinney E, Serreze DV, Chen YG) Immunogenetics 2017 Mar;69(3):193-198 2 Citations |
| 1 | Total pancreatectomy with islet autotransplantation: summary of a National Institute of Diabetes and Digestive and Kidney diseases workshop. (Bellin MD, Gelrud A, Arreaza-Rubin G, Dunn TB, Humar A, Morgan KA, Naziruddin B, Rastellini C, Rickels MR, Schwarzenberg SJ, Andersen DK) Pancreas 2014 Nov;43(8):1163-71 41 Citations |
| 2 | Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. (Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, Carter SL, Wu J, Wingard JR, Difronzo NL, Ferrara JL, Giralt S, Madtes DK, Drexler R, White ES, Cooke KR) Biol Blood Marrow Transplant 2014 Jun;20(6):858-64 59 Citations |
| 1 | Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302. (Bolaños-Meade J, Wu J, Logan BR, Levine JE, Ho VT, Alousi AM, Weisdorf DJ, Luznik L, Blood and Marrow Transplant Clinical Trials Network) Biol Blood Marrow Transplant 2013 Mar;19(3):481-5 5 Citations |
| 1 | Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. (Pariser DM, Leonardi CL, Gordon K, Gottlieb AB, Tyring S, Papp KA, Li J, Baumgartner SW) J Am Acad Dermatol 2012 Aug;67(2):245-56 66 Citations |
| 1 | Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. (Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A) JAMA 2011 Aug 24;306(8):864-71 259 Citations |
| 1 | Combination therapy with methotrexate and etanercept for refractory chronic recurrent multifocal osteomyelitis. (Eisenstein EM, Syverson GD, Vora SS, Williams CB) J Rheumatol 2011 Apr;38(4):782-3 23 Citations |
| 1 | Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. (Portman MA, Olson A, Soriano B, Dahdah N, Williams R, Kirkpatrick E) Am Heart J 2011 Mar;161(3):494-9 37 Citations |
| 1 | Graft-versus-host disease treatment: predictors of survival. (Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolaños-Meade J, Weisdorf D, Blood and Marrow Transplant Clinical Trials Network) Biol Blood Marrow Transplant 2010 Dec;16(12):1693-9 84 Citations |
| 3 | Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. (Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE, Blood and Marrow Transplant Clinical Trials Network) Blood 2009 Jul 16;114(3):511-7 186 Citations |
| 1 | Myasthenia gravis associated with etanercept therapy. (Fee DB, Kasarskis EJ) Muscle Nerve 2009 Jun;39(6):866-70 52 Citations |
| 1 | Rethinking eligibility creep. (Kazanis M, Leonardi C, Gordon K, Strober B, Menter A, Kimball AB) J Am Acad Dermatol 2008 Jul;59(1):165-7; author reply 167 1 Citation |
| 1 | Severe long-standing dysimmune sensory neuronopathy responsive to etanercept. (Figueroa JJ, Tabechian D, Herrmann DN) J Clin Neuromuscul Dis 2008 Jun;9(4):415-20 7 Citations |
| 1 | Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. (Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A) J Am Acad Dermatol 2008 May;58(5):851-64 384 Citations |
| 1 | Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R) J Am Acad Dermatol 2008 May;58(5):826-50 1162 Citations |
| 1 | Isolation of signal transduction complexes using biotin and crosslinking methodologies. (Freed JK, Smith JR, Li P, Greene AS) Proteomics 2007 Jul;7(14):2371-4 12 Citations |
| 1 | A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. (Cohen SP, Wenzell D, Hurley RW, Kurihara C, Buckenmaier CC 3rd, Griffith S, Larkin TM, Dahl E, Morlando BJ) Anesthesiology 2007 Jul;107(1):99-105 89 Citations |
| 1 | Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. (Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A) Arch Dermatol 2007 Jun;143(6):719-26 313 Citations |
| 1 | Mouse model of oral infection with virulent type A Francisella tularensis. (KuoLee R, Zhao X, Austin J, Harris G, Conlan JW, Chen W) Infect Immun 2007 Apr;75(4):1651-60 28 Citations |
| 1 | A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. (Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR) J Am Acad Dermatol 2007 Apr;56(4):598-603 149 Citations |
| 1 | Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. (Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ) Mol Cancer Ther 2006 Sep;5(9):2251-60 124 Citations |
| 1 | Cytomegalovirus (CMV)-encoded UL144 (truncated tumor necrosis factor receptor) and outcome of congenital CMV infection. (Arav-Boger R, Battaglia CA, Lazzarotto T, Gabrielli L, Zong JC, Hayward GS, Diener-West M, Landini MP) J Infect Dis 2006 Aug 15;194(4):464-73 55 Citations |
| 1 | The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. (Gordon KB, Ruderman EM) J Am Acad Dermatol 2006 Mar;54(3 Suppl 2):S85-91 34 Citations |
| 1 | Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. (Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T) J Am Acad Dermatol 2006 Mar;54(3 Suppl 2):S101-11 88 Citations |
| 1 | Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. (Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, Zitnik R) J Dermatolog Treat 2006;17(1):9-17 108 Citations |
| 1 | Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. (Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R) Lancet 2006 Jan 07;367(9504):29-35 968 Citations |
| 1 | Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. (Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ) J Immunother 2005;28(5):449-60 32 Citations |
| 1 | The role of the polio virus receptor and the herpesvirus entry mediator B genes for the development of MS. (Rosche B, Cepok S, Stei S, Vogel F, Grummel V, Hoffmann S, Kroner A, Mäurer M, Rieckmann P, Sommer N, Hemmer B) J Neuroimmunol 2004 Nov;156(1-2):171-7 8 Citations |
| 1 | Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. (Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R) J Am Acad Dermatol 2004 Aug;51(2):200-4 28 Citations |
| 1 | Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. (Yan X, Johnson BD, Orentas RJ) Immunology 2004 May;112(1):105-16 30 Citations |
| 1 | A randomized trial of etanercept as monotherapy for psoriasis. (Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R) Arch Dermatol 2003 Dec;139(12):1627-32; discussion 1632 454 Citations |
| 2 | Polymorphisms of the cytomegalovirus (CMV)-encoded tumor necrosis factor-alpha and beta-chemokine receptors in congenital CMV disease. (Arav-Boger R, Willoughby RE, Pass RF, Zong JC, Jang WJ, Alcendor D, Hayward GS) J Infect Dis 2002 Oct 15;186(8):1057-64 99 Citations |
| 1 | Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. (Tsimberidou AM, Thomas D, O'Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian H, Giles F) Cancer Chemother Pharmacol 2002 Sep;50(3):237-42 23 Citations |
| 1 | TNF receptor I mediates chemokine production and neutrophil accumulation in the lung following systemic lipopolysaccharide. (Calkins CM, Heimbach JK, Bensard DD, Song Y, Raeburn CD, Meng X, McIntyre RC Jr) J Surg Res 2001 Dec;101(2):232-7 36 Citations |
| 1 | A low level of TNF-alpha mediates hemorrhage-induced acute lung injury via p55 TNF receptor. (Song Y, Ao L, Raeburn CD, Calkins CM, Abraham E, Harken AH, Meng X) Am J Physiol Lung Cell Mol Physiol 2001 Sep;281(3):L677-84 61 Citations |
| 1 | TNF receptor I is required for induction of macrophage heat shock protein 70. (Heimbach JK, Reznikov LL, Calkins CM, Robinson TN, Dinarello CA, Harken AH, Meng X) Am J Physiol Cell Physiol 2001 Jul;281(1):C241-7 15 Citations |
| 1 | Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. (Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK) N Engl J Med 2000 Mar 16;342(11):763-9 1128 Citations |
| 1 | Tumor necrosis factor-induced E-selectin expression on vascular endothelial cells. (Gedeit RG) Crit Care Med 1996 Sep;24(9):1543-6 16 Citations |
| 1 | Linkage mapping of the tumor necrosis factor receptor 2 (TNFR2) gene to 1p36.2 using the single-strand conformation polymorphism technique. (Kaufman BA, White PS, Steinbrueck T, Donis-Keller H, Brodeur GM) Hum Genet 1994 Oct;94(4):418-22 10 Citations |
| 1 | Characterization of the region of consistent deletion within 1p36 in neuroblastomas. (White PS, Fujimori M, Marshall HN, Kaufman BA, Brodeur GM) Prog Clin Biol Res 1994;385:3-9 5 Citations |
| 1 | A complex single strand conformational polymorphism (SSCP) in the tumor necrosis factor receptor 2 (TNFR2) gene on chromosome 1p36.2. (Kaufman BA, White PS, Brodeur G) Hum Mol Genet 1993 Jun;2(6):824 9 Citations |
| 1 | Use of the single-strand conformation polymorphism technique to detect loss of heterozygosity in neuroblastoma. (White PS, Kaufman BA, Marshall HN, Brodeur GM) Genes Chromosomes Cancer 1993 Jun;7(2):102-8 34 Citations |
| 1 | Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. (Ferrajoli A, Talpaz M, Kurzrock R, Estrov Z) Stem Cells 1993 Mar;11(2):112-9 16 Citations |
| 1 | Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. (Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB) J Exp Med 1993 Mar 01;177(3):763-74 82 Citations |
